Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol.

Autor: Peter EL; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda. epeter@std.must.ac.ug.; Department of Innovation, Technology Transfer & Commercialization, National Institute for Medical Research, 2448 Baracka Obama drive, P.O. Box 9653, Dar Es Salaam, Tanzania. epeter@std.must.ac.ug., Deyno S; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.; Department of Pharmacology, School of Medicine, College of Medicine and Health Sciences, Hawassa University, Awasa, Ethiopia., Mtewa A; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.; Chemistry Section, Department of Applied Sciences, Malawi Institute of Technology, Malawi University of Science & Technology, Limbe, Malawi., Kasali FM; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.; Department of Pharmacy, Faculty of Medicine and Pharmacy, Official University of Bukavu, Bukavu, Democratic Republic of Congo., Nagendrappa PB; School of Integrative Health Sciences, Trans-disciplinary University, Bengaluru, India., Sesaazi D; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda., Tolo CU; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda., Ogwang PE; Pharm-BioTechnology and Traditional Medicine Center, World Bank-Africa Center of Excellence (ACE II), Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
Jazyk: angličtina
Zdroj: Systematic reviews [Syst Rev] 2018 Nov 15; Vol. 7 (1), pp. 192. Date of Electronic Publication: 2018 Nov 15.
DOI: 10.1186/s13643-018-0847-x
Abstrakt: Background: Momordica charantia Linnaeus (Cucurbitaceae) has been used traditionally as a nutritious food and as a herbal medicine for type 2 diabetes mellitus. However, human studies that investigated its glycemic control have generated inconsistent findings. Therefore, this systematic review and meta-analysis is aimed at evaluating the safety and efficacy of M. charantia L. preparations in human studies that have investigated its role in glycemic control.
Methods: This protocol has been prepared according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). The review will include randomized clinical trials and non-randomized clinical trials. The included studies will have assessed glycemic control of M. charantia preparations with placebo or standard oral anti-hyperglycemic agents in adult pre-diabetes and/or type 2 diabetes mellitus patients and have at least 4 weeks of follow-up. The primary outcomes of review are fasting blood glucose levels, glycosylated hemoglobin A1c, and post-prandial blood glucose level. Electronic database search for published literatures will be conducted without language restriction in EMBASE, MEDLINE/PubMed, the Cochrane Library, SCOPUS, Web of Sciences, and CINAHL databases. Search for gray literatures and references of the retrieved full-text articles will be conducted in Google, Google Scholar, OpenGrey, ProQuest dissertations & Theses, British Library EThos, and university digital library systems. Two independent reviewers will later evaluate full texts, extract data, and assess risk of bias of eligible articles. Publication biases will be assessed by testing asymmetry of funnel plot using Egger's or Begg's tests while heterogeneity will be assessed using Cochran Q test, P value, and I 2 . Revman software version 5.3 will be used for meta-analysis including subgroup and sensitivity analysis.
Discussion: This systematic review and meta-analysis will investigate both safety and efficacy of M. charantia preparations in type 2 diabetes mellitus. The review results will be published in a peer-reviewed journal. The results will bring better understanding of clinical outcomes in treatment of type 2 diabetes mellitus patients and highlight gaps for future research.
Systematic Review Registration: PROSPERO CRD42018083653 .
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje